Publications 2024

Anisdahl K, Lirhus SS, Medhus AW, Moum B, Melberg HO, Høivik ML (2024)
Frailty risk and treatment strategy in elderly-onset inflammatory bowel disease. A Norwegian nationwide population-based registry study
Dig Liver Dis, 56 (9), 1503-1510
DOI 10.1016/j.dld.2024.02.002, PubMed 38433021

Wiken TH, Høivik ML, Anisdahl K, Buer L, Warren DJ, Bolstad N, Hagen M, Moum BA, Medhus AW (2024)
Subcutaneous Vedolizumab Treatment in a Real-World Inflammatory Bowel Disease Cohort Switched From Intravenous Vedolizumab: Eighteen-Month Prospective Follow-up Study
Crohns Colitis 360, 6 (1), otae013
DOI 10.1093/crocol/otae013, PubMed 38544907

Publications 2023

Jørgensen KK, Høivik ML, Chopra A, Benth JŠ, Ricanek P, Moum PB, Jyssum I, Bolstad N, Warren DJ, Vaage PJT, Munthe PLA, Lundin PKEA, Anisdahl K, Syversen SW, Goll GL, Lund-Johansen F, Medhus AW, Jahnsen PJ (2023)
Humoral immune response to SARS-CoV-2 vaccination in patients with inflammatory bowel disease on immunosuppressive medication: association to serum drug levels and disease type
Scand J Gastroenterol, 58 (8), 874-882
DOI 10.1080/00365521.2023.2177884, PubMed 36788656

Wiken TH, Høivik ML, Buer L, Warren DJ, Bolstad N, Moum BA, Anisdahl K, Småstuen MC, Medhus AW (2023)
Switching from intravenous to subcutaneous vedolizumab maintenance treatment in patients with inflammatory bowel disease followed by therapeutic drug monitoring
Scand J Gastroenterol, 58 (8), 863-873
DOI 10.1080/00365521.2023.2176252, PubMed 36799155

Publications 2022

Zhao M, Lirhus S, Lördal M, Langholz E, Knudsen T, Voutilainen M, Høivik ML, Moum B, Anisdahl K, Saebø B, Haiko P, Malmgren C, Coskun M, Melberg HO, Burisch J (2022)
Therapeutic management and outcomes in inflammatory bowel diseases, 2010 to 2017 in cohorts from Denmark, Sweden and Norway
Aliment Pharmacol Ther, 56 (6), 989-1006
DOI 10.1111/apt.17145, PubMed 35902223

Publications 2021

Anisdahl K, Svatun Lirhus S, Medhus AW, Moum B, Melberg HO, Høivik ML (2021)
First-line biologic treatment of inflammatory bowel disease during the first 12 months after diagnosis from 2010 to 2016: a Norwegian nationwide registry study
Scand J Gastroenterol, 56 (10), 1163-1168
DOI 10.1080/00365521.2021.1955147, PubMed 34320885

Lirhus SS, Høivik ML, Moum B, Anisdahl K, Melberg HO (2021)
Incidence and Prevalence of Inflammatory Bowel Disease in Norway and the Impact of Different Case Definitions: A Nationwide Registry Study
Clin Epidemiol, 13, 287-294
DOI 10.2147/CLEP.S303797, PubMed 33935519